RxDoctor Payments Data

Heather Roberts

Family · Cheyenne, WYNPI 1134302037

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.1% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 36.7% of the total. Reporting peaked in 2022 at $777 and has fallen 53.7% since, to $360 in 2025. Among family clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,226in general payments, 2019–2025

Across 126 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$817
  • Novartis$366
  • Regeneron Healthcare Solutions, Inc.$179
  • Sanofi$158
  • Johnson & Johnson$150
  • Amgen$133
  • plus $423 from 10 others

What the payments were for

  • Food & beverage$2,02791%
  • Education$1999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,226 in reported general payments places this provider in the 90th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$345,377
Medicare patients
1,027
Services billed
5,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$86,390
OtezlaApremilast12$58,345
Clobetasol Propionate98$5,805
Fluorouracil62$5,294
Ketoconazole115$2,253
Doxycycline Hyclate63$1,592
Metronidazole23$1,373
Clindamycin Phosphate37$1,119
Tretinoin13$1,019
Mupirocin63$552
Triamcinolone Acetonide74$489
Minocycline Hcl16$475
ValacyclovirValacyclovir Hcl22$432
Doxycycline Monohydrate13$384
Hydroxychloroquine Sulfate13$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$133$58,34512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 284 family providers in Wyoming.

Other family in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →